OR WAIT null SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
Jill Wechsler is BioPharm International's Washington Editor, email@example.com.
Democrats failed to gain sufficient support to advance long-debated legislation to permit Medicare drug price negotiations.
The White House announced a nearly $3 billion program to ramp up production of vaccines and their components.
Will FDA’s approval of Semglee create a surge in the development of interchangeable biosimilars?
FDA formally unveiled its plan for revising and renewing its fee program for drugs and biologics.